Stories

The IRE Resource Center is a major research library containing more than 27,000 investigative stories.

Most of our stories are not available for download but can be easily ordered by contacting the Resource Center directly at 573-882-3364 or rescntr@ire.org where a researcher can help you pinpoint what you need.

Search results for "pharmaceutical" ...

  • Bottle of Lies: The Inside Story of the Generic Drug Boom

    The widespread use of generic drugs has been hailed as one of the most important public health developments of the twenty-first century. Today, 90 percent of the U.S. pharmaceutical market is comprised of generic drugs, the majority of which are manufactured overseas. We have been reassured by our doctors, our pharmacists and our regulators that generic drugs are identical to their brand-name counterparts, just less expensive. But is this really true? Bottle of Lies: The Inside Story of the Generic Drug Boom exposes for the first time the endemic fraud behind generic drug manufacturing –and the attendant risks for global public health.The narrative investigation interweaves the stories of a determined whistleblower, an intrepid FDA investigator and drug manufacturers determined to deceive regulators. Reported on four continents over a ten-year period, and drawing on 20,000 pages of confidential FDA documents, the book uncovers how one of the world’s greatest public health innovations also became one of its most astonishing swindles. Bottle of Lies uncovers a global industry where companies routinely falsify quality data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects.
  • Medicaid, Under the Influence

    Medicaid, Under the Influence: A joint investigation by the Center for Public Integrity and NPR showed how the pharmaceutical industry has infiltrated nearly every part of the often opaque process that determines how their drugs will be covered by taxpayers.
  • The Center for Public Integrity and NPR: Medicaid, Under the Influence

    A joint investigation by the Center for Public Integrity and NPR produced a damning examination of one key reason why Medicaid costs are soaring: The pharmaceutical industry has infiltrated the systems that states use to control Medicaid drug costs.
  • The DEA Dilemma

    An investigation of the DEA’s enforcement efforts against pharmaceutical distributors in the face of the nation’s opioid epidemic.
  • The Drug Trade

    Our graphic story and accompanying interactive summarized an analysis of generic and brand-name price increases for thousands of drugs. While smaller startup and investment companies grabbed headlines with dramatic increases in drug prices, our investigation showed that big pharmaceutical companies like AstraZeneca and Novartis raised prices by as much as 250 times over three years.
  • Dollars for Docs

    ProPublica first published Dollars for Docs, our comprehensive database of payments to doctors made by pharmaceutical companies for speaking, consulting, etc., in 2010. Millions of people have looked up their doctors, and hundreds of news organizations have used the data to tell important investigative stories. But it was only this year that, thanks to some painstaking work, we were able to match pharmaceutical payments with prescribing habits. And our findings were dispositive: Doctors who take payments tend to prescribe more brand-name drugs. Moreover, thousands of doctors who have had disciplinary actions against them by their state licensing boards are still getting pharma payments, and a greater share of physicians who work at for-profit hospitals take payments compared to those working at nonprofit or government facilities. https://projects.propublica.org/docdollars/ https://projects.propublica.org/graphics/d4d-hospital-lookup
  • Revealed: Pfizer's Payments To Censured Doctors

    They are as billed as "healthcare professionals who spend years building expertise in their fields." Using material surrounded in science, they educate their peers in the risks and benefits of drugs. This is how Pfizer, the pharmaceuticals giant, describes the experts it hires to lead forums in which doctors are lectured on the use of its products.
  • Healthcare crisis, Corp. Fraud

    SIRF's work in exposing how Valeant, a high-flying pharmaceutical company, concealed its ownership of a specialty pharmacy that helped it to massive profits led to a multi-month drama that saw its share price cut by 75%, subpoena's and the closure of the unit.
  • Risk/Reward

    An investigation into the nation’s flawed system for approving new drugs, which allows pharmaceutical companies to produce expensive products of dubious value that put patients at risk.
  • Failure to report: a STAT investigation - Law ignored, patients at risk

    These stories examined how well the nation’s leading clinical research organizations followed the federal law that requires them to report publicly the results of completed clinical trials – experiments involving human subjects. We found that Stanford University, Memorial Sloan Kettering Cancer Center, and other prestigious medical research institutions flagrantly violated the law, depriving patients and doctors of complete data to gauge the safety and benefits of treatments. Nearly all other institutions – including pharmaceutical companies – flouted the requirements routinely. The failure to report has left gaping holes in the federal ClinicalTrials.gov database used by millions of patients, their relatives, and medical professionals, often to compare the effectiveness and side effects of treatments for deadly diseases. The worst offenders included four of the top 10 recipients of research funding from the National Institutes of Health, all of which disclosed results late or not at all at least 95 percent of the time since reporting became mandatory in 2008. http://www.statnews.com/2015/12/13/clinical-trials-investigation-methodology/ http://www.statnews.com/2015/12/13/clinical-trials-investigation/